Halozyme Therapeutics (HALO) EBITDA Margin (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly EBITDA Margin of 48.98% for Q1 2026, down 446.0% year-over-year from 14.16% in Q1 2025, and up 338.22% quarter-over-quarter from 20.56% in Q4 2025.
Halozyme Therapeutics (HALO) EBITDA Margin (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported EBITDA Margin for 17 consecutive years, with 48.98% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 446.0% year-over-year to 48.98%; the TTM figure through Mar 2026 stood at 33.94% (down 2116.0% YoY), while the FY2025 annual figure was 33.58%, down 2073.0% from the prior year.
- EBITDA Margin advanced to 48.98% in Q1 2026 per HALO's latest filing, from 20.56% in the prior quarter.
- Across five years, EBITDA Margin topped out at 64.52% in Q1 2022 and bottomed at 20.56% in Q4 2025.
- Historically, EBITDA Margin has averaged 44.04% across 5 years, with a median of 48.78% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin jumped 2038 bps — and 2025, when it tumbled 7945 bps.
- Halozyme Therapeutics' EBITDA Margin stood at 41.05% in 2022, then increased by 7 bps to 43.92% in 2023, then jumped by 34 bps to 58.89% in 2024, then tumbled by 135 bps to 20.56% in 2025, then jumped by 338 bps to 48.98% in 2026.
- Business Quant data shows HALO's EBITDA Margin at 48.98% in Q1 2026, 20.56% in Q4 2025, and 61.51% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 59.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.80% |
| Mar 31, 2026 | 48.98% |
| Dec 31, 2025 | -20.56% |
| Sep 30, 2025 | 61.51% |
| Jun 30, 2025 | 62.15% |
| Mar 31, 2025 | 53.44% |
| Dec 31, 2024 | 58.89% |
| Sep 30, 2024 | 56.26% |
| Jun 30, 2024 | 50.67% |
| Mar 31, 2024 | 48.78% |
| Dec 31, 2023 | 43.92% |
| Sep 30, 2023 | 40.86% |
| Jun 30, 2023 | 42.73% |
| Mar 31, 2023 | 33.18% |
| Dec 31, 2022 | 41.05% |
| Sep 30, 2022 | 39.86% |
| Jun 30, 2022 | 22.35% |
| Mar 31, 2022 | 64.52% |
| Dec 31, 2021 | 55.42% |
| Sep 30, 2021 | 65.26% |